Dignity Health® St. Rose Dominican

Study Objectives

- To evaluate the efficacy of pharmacy driven efforts to reduce continuous IV sedation and assess its appropriateness
- Collect and compare the number of days spent on mechanical ventilation before and after procedure initiation
- Compare and evaluate the average number of days a patient spends in the intensive care unit (ICU)

Background


- Sedation is standard treatment for patients undergoing mechanical ventilation
- Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) guidelines recommend managing pain prior to initiation of sedation
- Light sedation and spontaneous awakening trials (SATs) are also recommended
- Shorter durations of sedation and SATs have been shown to reduce ICU stays and mechanical ventilation days

Richmond Agitation & Sedation Scale (RASS				
Score	Description			
+ 4	Combative: Overtly combative, violent, immediate danger to sta			
+ 3	Very agitated: Pulls or removes tube(s) or catheter(s); aggressive			
+ 2	Agitated: Frequent non-purposeful movement, fights ventilator			
+ 1	Restless: Anxious but movements not aggressive vigorous			
0	Alert and calm			
- 1	Drowsy: Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (>10 seconds)			
- 2	Light sedation: Briefly awakens with eye contact to voice (<10 seconds)			
- 3	Moderate sedation: Movement or eye opening to voice (but no eye contact)			
- 4	Deep sedation: No response to voice, but movement or eye opening to physical stimulation			
- 5	Unarousable: No response to voice or physical stimulation			

Intervention

- Pharmacist performs daily review of patients on continuous sedation
- Patients not meeting exclusion criteria are discussed with licensed independent practitioner for continuous sedation stop

Background C



Characteristic

Age – yrs, mean (SD) Male, n (%) BMI, mean (SD) APACHE II score, mean (SD) COVID +, n (%) **Primary Outcomes** Vent days, mean (hrs) **Secondary Outcomes** All-cause mortality, n (%) CAM positive days, mean ICU days, mean RASS achieved off of continuous sedation, n (%) Continuous sedation days, mean (hrs) Continuous sedation restarted, n (%)

Prelimina

Characteristic

Primary Outcomes Vent days, mean (Hrs) **Secondary Outcomes** All-cause mortality, n (%) CAM positive days, mean ICU days, mean RASS achieved off of continuous sedation, n (%) Continuous sedation days, mean (Hrs) Continuous sedation restarted, n (%)

References

- Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous iv. sedation is associated with prolongation of mechanical ventilation. Chest 1998;114:541–8 Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/ sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018;46(9):e825-e873.
- Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999; 27: 2609–15
- 375(9713), 475-480. doi:10.1016/s0140-6736(09)62072-9
- Olsen HT, Nedergaard HK, Strøm T, Jakob O, Wian K-A, Ytrebø LM, et al. Nonsedation or light sedation in critically ill, mechanically ventilated patients. N Engl J Med. 2020;382(12):1103-11.

Effects of a Pharmacy Driven Continuous Sedation Stop Procedure on Mechanical Ventilation Days

Steven Burgos, PharmD; Karen Holmes, PharmD, BCPS; Christine Hackman, PharmD

Characteristics				
	Pre-Procedure (n=85)	Post-Procedure (n=114)		
	71 (6.36)	70 (5.7)		
	45 (53)	55 (48)		
	28.5 (4.56)	28.6 (12)		
	22 (0.7)	24 (0.7)		
	0 (0)	26 (23)		
	3.1 (74.4)	3.88 (93.2)		
	6 (7)	13 (12)		
	4	5		
	5.6	6.1		
	8 (9)	42 (37)		
	3.1 (74.4)	2.95 (70.8)		
		7 (6)		

ry Results				
	Pre-Procedure (n=85)	Post-Procedure (n=114)		
	3.1 (74.4)	3.88 (93.2)		
	6 (7)	13 (12)		
	4	5		
	5.6	6.1		
	8 (9)	42 (37)		
	3.1 (74.4)	2.95 (70.8)		
		7 (6)		

Strøm, T., Martinussen, T., & Toft, P. (2010, January 29). A protocol of no sedation for critically ill patients receiving mechanical ventilation: A randomised trial. The Lancet,

- Sample size: 456

MV/ICU patients

- Dexmedetomic
- Fentanyl
- Hydromorphor

• Comfort care

- Chronic MV/Training
- Death prior to
- High ventilator
- PEEP <u>></u>10) prio

• Primary

• Secondary

- All-cause mortality
- \circ ICU days

Methodology

• Retrospective chart review

Records from January 2019 to November 2022

• Data collected from Dignity Health St. Rose Dominican – Siena campus

Medical ICU and Surgical ICU

Inclusion				
s on continuous sedation for <u>></u> 48 hours				
idine	KetamineMidazolam			
one	 Propofol 			
Exclusion				
Tracheostomy 5 day 3 or settings (FiO ₂ <u>></u> 80%, or to day 3	 Induced hypothermia Neuromuscular blocker infusion Proning Seizures/Status Epilepticus Substance withdrawal 			

Outcomes

Number of ventilation days

 Confusion Assessment Method (CAM-ICU) positive days Continuous sedation days

○ Number of patients who have achieved RASS goal of -1 to +1 off of continuous sedation

Number of patients restarted on continuous sedation

Conclusion

Pending final outcome of results